Aligos Therapeutics (ALGS) FCF Margin Growth (1y) (2022 - 2026)
Powered by 
Analysis
Aligos Therapeutics (ALGS) FCF Margin Growth (1y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 1,388.00 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 3,383.00 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | -89.00 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | -1,183.00 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 26,102.00 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 769.00 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 984.00 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -902,489.00 |
| 10 | Aligos Therapeutics | 54.92 Mn | 24.48 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 590,591.00 |
| Dec 31, 2025 | -983,007.00 |
| Sep 30, 2025 | -167,735.00 |
| Jun 30, 2025 | 23,060.00 |
| Mar 31, 2025 | -344,563.00 |
| Dec 31, 2024 | -190,897.00 |
| Sep 30, 2024 | -66,398.00 |
| Jun 30, 2024 | -152,014.00 |
| Mar 31, 2024 | -241,055.00 |
| Dec 31, 2023 | -65,075.00 |
| Sep 30, 2023 | -52,667.00 |
| Jun 30, 2023 | 36,985.00 |
| Mar 31, 2023 | -5,216.00 |
| Dec 31, 2022 | 982,702.00 |
| Sep 30, 2022 | 123,936.00 |
| Jun 30, 2022 | 81,273.00 |
| Mar 31, 2022 | 249,320.00 |